Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group

Valerie Cristina; Jestinah Mahachie; Murielle Mauer; Thierry Buclin; Eric Van Cutsem; Arnaud Roth; Anna D Wagner

doi:10.1001/jamaoncol.2018.1080

Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group

JAMA Oncol. 2018 Jul 1;4(7):1003-1006. doi: 10.1001/jamaoncol.2018.1080.

Authors

Valerie Cristina¹, Jestinah Mahachie², Murielle Mauer², Thierry Buclin³, Eric Van Cutsem⁴, Arnaud Roth^{5

6}, Anna D Wagner^{1

6}

Affiliations

¹ Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
² Statistics Department, EORTC Headquarters, Brussels, Belgium.
³ Department of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland.
⁴ Department of Digestive Oncology, University Hospitals Leuven and KU, Leuven, Belgium.
⁵ Department of Oncology, Hôpitaux Universitaire de Genève, Geneva, Switzerland.
⁶ Project Group Gastro-Intestinal Cancer, SAKK, Bern, Switzerland.

Abstract

This secondary analysis of the PETACC-3 trial examines the association of sex with incidence and severity of chemotherapy-related toxic effects in patients with stage II and III colorectal cancer treated with fluorouracil and leucovorin with or without irinotecan hydrochloride.

Publication types

Letter

MeSH terms

Aged
Drug Therapy / methods*
Drug-Related Side Effects and Adverse Reactions / epidemiology*
Female
Gastrointestinal Neoplasms / complications*
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / pathology
Gender Identity*
Humans
Male
Middle Aged
Retrospective Studies